• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Examination of EGCG modified liposome for targeting malignant tumor and apoptosis induction

Research Project

Project/Area Number 25860121
Research Category

Grant-in-Aid for Young Scientists (B)

Allocation TypeMulti-year Fund
Research Field Medical pharmacy
Research InstitutionIwate Medical University

Principal Investigator

SUGIYAMA Ikumi  岩手医科大学, 薬学部, 助教 (80509050)

Project Period (FY) 2013-04-01 – 2015-03-31
Project Status Completed (Fiscal Year 2014)
Budget Amount *help
¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Keywordsリポソーム / EGCG / ラミニンレセプター
Outline of Final Research Achievements

The aim of this study is increase of antitumor effect and decrease of adverse effect by liposomes which have high affinity with 67 kDa laminin receptor (67LR). When (-)-epigallocatechin-3-gallate (EGCG) as one of the green tea polyphenol are connected with 67LR, apoptosis is induced on tumor cells. Then we have studied about EGCG modified liposome containing antitumor agent as drug delivery system. It was suggested that this effect was mediated with 67LR needed gallate base in the structure of EGCG. In mice experiment, EGCG-modified liposome rapidly disappeared from the blood circulation after injection. However, EGCG-modifieed liposome with polyethylenglycol (PEG) had long circulation time in blood. Moreover, the cytotoxicity of EGCG-PEG-modified liposome was stronger than EGCG-modified liposome. In conclusion, it was expected that EGCG-PEG-modified liposome increases targeted ability to tumor cells and antitumor activity.

Report

(3 results)
  • 2014 Annual Research Report   Final Research Report ( PDF )
  • 2013 Research-status Report
  • Research Products

    (6 results)

All 2015 2014 2013

All Presentation (6 results)

  • [Presentation] The advanced strategy for novel EGCG derivative modified liposome with high targeting ability to tumor2015

    • Author(s)
      杉山育美、佐塚泰之
    • Organizer
      Annual Meeting 2015 of the American Association for Cancer Research
    • Place of Presentation
      Philadelphia (USA)
    • Year and Date
      2015-04-22
    • Related Report
      2014 Annual Research Report
  • [Presentation] 悪性腫瘍に高発現するエピガロカテキンガレ-ト受容体を標的とした薬物キャリアの検討2014

    • Author(s)
      杉山育美、開發邦宏、加藤修雄、佐塚泰之
    • Organizer
      第11回日本カテキン学会年次学術大会
    • Place of Presentation
      昭和大学(東京都品川区)
    • Year and Date
      2014-11-22
    • Related Report
      2014 Annual Research Report
  • [Presentation] 67kDaラミニンレセプタ-を標的としたEGCG修飾リポソ-ムの体内動態評価2014

    • Author(s)
      杉山育美、佐塚泰之
    • Organizer
      第73回日本癌学会総会
    • Place of Presentation
      パシフィコ横浜(神奈川県横浜市)
    • Year and Date
      2014-09-27
    • Related Report
      2014 Annual Research Report
  • [Presentation] (-)-Epigallocatechin-3-gallate 修飾リポソ-ムの有用性検討2014

    • Author(s)
      杉山育美、開發邦宏、加藤修雄、佐塚泰之
    • Organizer
      日本薬剤学会第 29 年会
    • Place of Presentation
      大宮ソニックスティビル(埼玉県さいたま市)
    • Year and Date
      2014-05-22
    • Related Report
      2014 Annual Research Report
  • [Presentation] Liposomal Doxorubicin with Modified EGCG Increased Antitumor Activity by Topical Targeting Efficacy into Tumor2014

    • Author(s)
      杉山育美、佐塚泰之
    • Organizer
      Annual Meeting 2014 of the American Association for Cancer Research
    • Place of Presentation
      San Diego (USA)
    • Year and Date
      2014-04-09
    • Related Report
      2014 Annual Research Report
  • [Presentation] Laminin receptor targeted liposome with EGCG modification to increase antitumor effect2013

    • Author(s)
      杉山 育美
    • Organizer
      第72回 日本癌学会学術総会
    • Place of Presentation
      パシフィコ横浜
    • Related Report
      2013 Research-status Report

URL: 

Published: 2014-07-25   Modified: 2019-07-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi